These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10656221)

  • 21. [Acarbose-induced acute hepatitis. Report of two events in the same patient].
    de la Vega J; Crespo M; Escudero JM; Sánchez L; Rivas LL
    Gastroenterol Hepatol; 2000; 23(6):282-4. PubMed ID: 15324623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.
    Paroni R; Comuzzi B; Arcelloni C; Brocco S; de Kreutzenberg S; Tiengo A; Ciucci A; Beck-Peccoz P; Genovese S
    Clin Chem; 2000 Nov; 46(11):1773-80. PubMed ID: 11067812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
    Lee YH; Lee CJ; Lee HS; Choe EY; Lee BW; Ahn CW; Cha BS; Lee HC; Balkau B; Kang ES
    Diabetes Metab; 2015 Jun; 41(3):208-15. PubMed ID: 25687901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acute cholestatic hepatitis induced by glimepiride].
    Sitruk V; Mohib S; Grando-Lemaire V; Ziol M; Trinchet JC
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1233-4. PubMed ID: 11173739
    [No Abstract]   [Full Text] [Related]  

  • 25. The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
    Clemens KK; McArthur E; Dixon SN; Fleet JL; Hramiak I; Garg AX
    Can J Diabetes; 2015 Aug; 39(4):308-16. PubMed ID: 25840942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Wascher TC; Boes U
    Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Not Available].
    Viardot A
    Ther Umsch; 2017; 74(8):423-431. PubMed ID: 29461148
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide.
    Lee JY; Kim G; Lee YH; Lee BW; Cha BS; Nam CM; Kang ES
    Diabetes Metab; 2019 Jan; 45(1):83-85. PubMed ID: 28778564
    [No Abstract]   [Full Text] [Related]  

  • 29. Metformin-induced acute hepatitis.
    Babich MM; Pike I; Shiffman ML
    Am J Med; 1998 May; 104(5):490-2. PubMed ID: 9626034
    [No Abstract]   [Full Text] [Related]  

  • 30. Possible gliclazide-induced water retention with azotemia.
    Kamikubo K; Takami R; Suwa T; Sugiyama A; Horibe N; Sakata S
    Intern Med; 1994 Mar; 33(3):163-4. PubMed ID: 8061394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diclofenac-associated acute cholestatis hepatitis].
    Hackstein H; Mohl W; Püschel W; Stallmach A; Zeitz M
    Z Gastroenterol; 1998 May; 36(5):385-9. PubMed ID: 9654706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
    Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenytoin-induced chronic hepatitis.
    Roy AK; Mahoney HC; Levine RA
    Dig Dis Sci; 1993 Apr; 38(4):740-3. PubMed ID: 8462373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-induced Liver injury Caused by Ipragliflozin Administration with Causality Established by a Positive Lymphocyte Transformation Test (LTT) and the Roussel Uclaf Causality Assessment Method (RUCAM): A Case Report.
    Niijima K; Niijima Y; Okada S; Yamada M
    Ann Hepatol; 2017; 16(2):308-311. PubMed ID: 28233736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular injury in a patient receiving rosiglitazone. A case report.
    Al-Salman J; Arjomand H; Kemp DG; Mittal M
    Ann Intern Med; 2000 Jan; 132(2):121-4. PubMed ID: 10644273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Mbanya JC; Al-Sifri S; Abdel-Rahim A; Satman I
    Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rhabdomyolysis induced by fenofibrate monotherapy].
    Archambeaud-Mouveroux F; Lopez S; Combes C; Lassandre S; Amaniou M; Teissier MP; Galinat S
    Rev Med Interne; 2006 Jul; 27(7):573-4. PubMed ID: 16716459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gliclazide modified release.
    McGavin JK; Perry CM; Goa KL
    Drugs; 2002; 62(9):1357-64; discussion 1365-6. PubMed ID: 12076188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.